Sells mesh-covered carotid stents for carotid artery disease to medical-product distributors and to U.S. interventional and surgical specialists.
10-K for FY2025, filed Mar 18, 2026We are a medical device company specializing in the development and commercialization of products for the treatment of carotid artery…View ↗
Our first product, the CGuard Carotid Embolic Prevention System (“CGuard EPS”), integrates a self-expanding nitinol stent with a MicroNet…View ↗
Our second product, the CGuard Prime Carotid Stent System (“CGuard Prime”), uses the same stent and MicroNet mesh as the CGuard EPS with a…View ↗
Our customer base is varied. We currently have distribution agreements for our CE mark-approved CGuard EPS with medical product…View ↗
Since PMA approval in the U.S., our direct sales organization has built and supported a varied customer base of multiple interventional and…View ↗
Distributors and medical centers pay for products when they ship or are delivered, depending on the contract’s shipping terms.
10-K for FY2025, filed Mar 18, 2026Revenue from sales of goods, including sales to distributors and direct sales to medical centers, is recognized at the point in time when…View ↗
$9M
10-K for FY2025, filed Mar 18, 2026
$9M ↗
Outside the United States, medical-product distributors buy CGuard EPS and handle local sales and marketing. In the United States, a direct sales organization serves interventional and surgical specialists.
10-K for FY2025, filed Mar 18, 2026Our customer base is varied. We currently have distribution agreements for our CE mark-approved CGuard EPS with medical product…View ↗
Our distribution agreements stipulate that, while we shall assist in training by providing training materials, marketing guidance…View ↗
Since PMA approval in the U.S., our direct sales organization has built and supported a varied customer base of multiple interventional and…View ↗
10-K for FY2025, filed Mar 18, 2026
2025 2024 Year ended December 31, 2025 2024 Customer A 14 % 13 % Customer B 12 % 10 % Customer C - 10 % Sales percentage - 10 %View ↗
No. It lost $48.8M in FY2025.
10-Q for Q2 FY2026, filed Aug 14, 2026
−$14.3MView ↗
8-K, filed Nov 12, 2026
On November 12, 2026, the Company announced that the U.S. Food and Drug Administration has approved the Company’s Premarket Approval…View ↗
Growing. Revenue grew 100% in 4 years, from $4.5M in FY2021 to $9M in FY2025, about 19% a year.
U.S. CGuard Prime sales
The older report described CGuard Prime as a product in development and subject to regulatory approval; the latest says it is FDA-approved and sold in the United States through a direct salesforce.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 18, 2026The CGuard Prime™ System is a mesh-covered self-expanding carotid stent that is loaded into a transfemoral rapid exchange (Rx) delivery…View ↗
Our second product, the CGuard Prime Carotid Stent System (“CGuard Prime”), uses the same stent and MicroNet mesh as the CGuard EPS with a…View ↗
Broader patient group
The older report framed CGuard EPS around symptomatic high-grade carotid narrowing; the latest describes its addressable group as symptomatic and asymptomatic patients eligible for carotid stenting, TCAR, or surgery.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 18, 2026We consider our current addressable market for our CGuard EPS to be individuals with diagnosed, symptomatic high-grade carotid artery…View ↗
We consider our current addressable market for our CGuard EPS, CGuard Prime, and SwitchGuard NPS to be both symptomatic and asymptomatic…View ↗
Competes with Abbott Laboratories, Boston Scientific, Medtronic, Cordis, and Terumo Medical
10-K for FY2025, filed Mar 18, 2026With respect to competition for our carotid embolic prevention systems, CGuard EPS and CGuard Prime, the manufacturers of products used in…View ↗
Loading...